Erlotinib Tablets IP

Product Description

Here are some frequently asked questions (FAQs) about Erlotinib Tablets IP:

1. What are Erlotinib Tablets IP?Erlotinib Tablets IP are a medication used to treat certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer.

2. How does Erlotinib Tablets IP work?Erlotinib is a tyrosine kinase inhibitor that works by blocking the activity of the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. By inhibiting EGFR, Erlotinib helps to slow down or stop the growth of cancer cells.

3. What conditions does Erlotinib Tablets IP treat?Erlotinib Tablets IP are primarily used in the treatment of non-small cell lung cancer (NSCLC) that has certain genetic mutations (such as EGFR mutations) and pancreatic cancer that has spread to other parts of the body.

4. How is Erlotinib Tablets IP administered?Erlotinib Tablets IP are taken orally (by mouth) once daily, with or without food. The dosage and duration of treatment will depend on the patient's specific condition, medical history, and treatment plan.

5. What are the common side effects of Erlotinib Tablets IP?Common side effects of Erlotinib Tablets IP may include rash, diarrhea, nausea, vomiting, loss of appetite, fatigue, and inflammation of the mouth and lips (stomatitis). Some patients may also experience changes in liver function tests and electrolyte levels.

6. Who should not take Erlotinib Tablets IP?Erlotinib Tablets IP may not be suitable for everyone. Patients with severe liver problems, a history of interstitial lung disease or pneumonitis, or a known hypersensitivity to Erlotinib or any of its components should not take Erlotinib Tablets IP. It's crucial to inform your healthcare provider about your medical history and any medications you are currently taking before starting Erlotinib Tablets IP.

7. Is Erlotinib Tablets IP safe during pregnancy and breastfeeding?Erlotinib Tablets IP may cause harm to a developing fetus and is not recommended for use during pregnancy. It is also not known whether Erlotinib Tablets IP passes into breast milk, so breastfeeding is typically not recommended while receiving treatment with Erlotinib Tablets IP. It's essential to discuss the risks and benefits with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

8. Are there any interactions with other medications?Erlotinib Tablets IP may interact with certain medications, including other cancer treatments and medications that affect liver function or gastric pH. It's crucial to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and supplements, to avoid potential interactions.